A Phase II trial of suramin monthly × 3 for hormone-refractory prostate carcinoma (pages 65–71)
Nicholas J. Vogelzang, Theodore Karrison, Walter M. Stadler, Juan Garcia, Helene Cohn, John Kugler, Thomas Troeger, Leonard Giannone, Rose Arrieta, Mark J. Ratain and Everett E. Vokes
Version of Record online: 10 NOV 2003 | DOI: 10.1002/cncr.11867
Suramin administered as a 1-hour bolus monthly × 3 to 58 patients with metastatic hormone-refractory prostate carcinoma induced declines (> 50%) in prostate-specific antigen (PSA) and objective responses with respect to measurable disease in 37.5% and 18.5% of patients, respectively. Responses with respect to PSA and pain also were observed in patients who were pretreated with chemotherapy.